{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:04:39Z","timestamp":1761865479960,"version":"build-2065373602"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08385, 23K07390"],"award-info":[{"award-number":["19K08385, 23K07390"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fk0310101h0002, JP23ama121038"],"award-info":[{"award-number":["JP18fk0310101h0002, JP23ama121038"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-10473-5","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:53:59Z","timestamp":1751936039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus"],"prefix":"10.1038","volume":"15","author":[{"given":"Kosuke","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitoshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masazumi","family":"Onuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Sawahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"10473_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/s2468-1253(23)00197-8","volume":"8","author":"PO Collaborators","year":"2023","unstructured":"Collaborators, P. O. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol. Hepatol. 8, 879\u2013907. https:\/\/doi.org\/10.1016\/s2468-1253(23)00197-8 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10473_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10, 1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4 (2016).","journal-title":"Hepatol. Int."},{"key":"10473_CR3","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/liv.14155","volume":"39","author":"P Marcellin","year":"2019","unstructured":"Marcellin, P. et al. Ten-year efficacy and safety of Tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 39, 1868\u20131875. https:\/\/doi.org\/10.1111\/liv.14155 (2019).","journal-title":"Liver Int."},{"key":"10473_CR4","doi-asserted-by":"publisher","unstructured":"Inoue, J., Sato, K., Ninomiya, M. & Masamune, A. Envelope proteins of hepatitis B virus: molecular biology and involvement in carcinogenesis. Viruses 13 https:\/\/doi.org\/10.3390\/v13061124 (2021).","DOI":"10.3390\/v13061124"},{"key":"10473_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.antiviral.2006.01.003","volume":"70","author":"M Asif-Ullah","year":"2006","unstructured":"Asif-Ullah, M., Choi, K. J., Choi, K. I., Jeong, Y. J. & Yu, Y. G. Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus. Antiviral Res. 70, 85\u201390. https:\/\/doi.org\/10.1016\/j.antiviral.2006.01.003 (2006).","journal-title":"Antiviral Res."},{"key":"10473_CR6","doi-asserted-by":"publisher","unstructured":"Inoue, J. et al. Small interfering RNA screening for the small GTPase Rab proteins identifies Rab5B as a major regulator of hepatitis B virus production. J. Virol. 93 https:\/\/doi.org\/10.1128\/jvi.00621-19 (2019).","DOI":"10.1128\/jvi.00621-19"},{"key":"10473_CR7","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen, M. F. et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl. J. Med. 387, 1957\u20131968. https:\/\/doi.org\/10.1056\/NEJMoa2210027 (2022).","journal-title":"N Engl. J. Med."},{"key":"10473_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1136\/gutjnl-2022-328041","volume":"72","author":"HLA Janssen","year":"2023","unstructured":"Janssen, H. L. A. et al. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut 72, 1385\u20131398. https:\/\/doi.org\/10.1136\/gutjnl-2022-328041 (2023).","journal-title":"Gut"},{"key":"10473_CR9","doi-asserted-by":"publisher","first-page":"e0201236","DOI":"10.1371\/journal.pone.0201236","volume":"13","author":"M Al Mahtab","year":"2018","unstructured":"Al Mahtab, M. et al. Treatment of chronic hepatitis B Na\u00efve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS One. 13, e0201236. https:\/\/doi.org\/10.1371\/journal.pone.0201236 (2018).","journal-title":"PLoS One"},{"key":"10473_CR10","doi-asserted-by":"publisher","first-page":"9350","DOI":"10.1128\/jvi.71.12.9350-9357.1997","volume":"71","author":"V Bruss","year":"1997","unstructured":"Bruss, V. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. J. Virol. 71, 9350\u20139357. https:\/\/doi.org\/10.1128\/jvi.71.12.9350-9357.1997 (1997).","journal-title":"J. Virol."},{"key":"10473_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1128\/jvi.77.1.416-422.2003","volume":"77","author":"D Ponsel","year":"2003","unstructured":"Ponsel, D. & Bruss, V. Mapping of amino acid side chains on the surface of hepatitis B virus capsids required for envelopment and virion formation. J. Virol. 77, 416\u2013422. https:\/\/doi.org\/10.1128\/jvi.77.1.416-422.2003 (2003).","journal-title":"J. Virol."},{"key":"10473_CR12","doi-asserted-by":"publisher","first-page":"10064","DOI":"10.1128\/jvi.01481-15","volume":"89","author":"X Cui","year":"2015","unstructured":"Cui, X., Luckenbaugh, L., Bruss, V. & Hu, J. Alteration of mature nucleocapsid and enhancement of covalently closed circular DNA formation by hepatitis B virus core mutants defective in Complete-Virion formation. J. Virol. 89, 10064\u201310072. https:\/\/doi.org\/10.1128\/jvi.01481-15 (2015).","journal-title":"J. Virol."},{"key":"10473_CR13","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1158\/1535-7163.Mct-21-0175","volume":"20","author":"DE Durrant","year":"2021","unstructured":"Durrant, D. E. et al. Development of a High-throughput NanoBRET screening platform to identify modulators of the RAS\/RAF interaction. Mol. Cancer Ther. 20, 1743\u20131754. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0175 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"10473_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1021\/acschembio.1c00826","volume":"17","author":"L Ganier","year":"2022","unstructured":"Ganier, L. et al. Discovery of Small-Molecule inhibitors of the PTK7\/\u03b2-Catenin interaction targeting the Wnt signaling pathway in colorectal Cancer. ACS Chem. Biol. 17, 1061\u20131072. https:\/\/doi.org\/10.1021\/acschembio.1c00826 (2022).","journal-title":"ACS Chem. Biol."},{"key":"10473_CR15","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1128\/jvi.70.9.5845-5851.1996","volume":"70","author":"VE Buckwold","year":"1996","unstructured":"Buckwold, V. E., Xu, Z., Chen, M., Yen, T. S. & Ou, J. H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 70, 5845\u20135851. https:\/\/doi.org\/10.1128\/jvi.70.9.5845-5851.1996 (1996).","journal-title":"J. Virol."},{"key":"10473_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1006\/viro.1996.0655","volume":"226","author":"K Moriyama","year":"1996","unstructured":"Moriyama, K., Okamoto, H., Tsuda, F. & Mayumi, M. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 226, 269\u2013280. https:\/\/doi.org\/10.1006\/viro.1996.0655 (1996).","journal-title":"Virology"},{"key":"10473_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1006\/viro.1997.8594","volume":"233","author":"PP Scaglioni","year":"1997","unstructured":"Scaglioni, P. P., Melegari, M. & Wands, J. R. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 233, 374\u2013381. https:\/\/doi.org\/10.1006\/viro.1997.8594 (1997).","journal-title":"Virology"},{"key":"10473_CR18","doi-asserted-by":"publisher","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","volume":"11","author":"M Al-Mahtab","year":"2016","unstructured":"Al-Mahtab, M., Bazinet, M. & Vaillant, A. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in Treatment-Naive Bangladeshi patients with HBeAg\u2009+\u2009Chronic hepatitis B infection. PLoS One. 11, e0156667. https:\/\/doi.org\/10.1371\/journal.pone.0156667 (2016).","journal-title":"PLoS One"},{"key":"10473_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/s2468-1253(17)30288-1","volume":"2","author":"M Bazinet","year":"2017","unstructured":"Bazinet, M. et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 2, 877\u2013889. https:\/\/doi.org\/10.1016\/s2468-1253(17)30288-1 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10473_CR20","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","volume":"158","author":"M Bazinet","year":"2020","unstructured":"Bazinet, M. et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, Tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection Na\u00efve to Nucleos(t)ide therapy. Gastroenterology 158, 2180\u20132194. https:\/\/doi.org\/10.1053\/j.gastro.2020.02.058 (2020).","journal-title":"Gastroenterology"},{"key":"10473_CR21","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/hep4.1767","volume":"5","author":"M Bazinet","year":"2021","unstructured":"Bazinet, M. et al. Analysis of HBsAg immunocomplexes and CccDNA activity during and persisting after NAP-Based therapy. Hepatol. Commun. 5, 1873\u20131887. https:\/\/doi.org\/10.1002\/hep4.1767 (2021).","journal-title":"Hepatol. Commun."},{"key":"10473_CR22","doi-asserted-by":"publisher","unstructured":"Hershkovich, L. et al. Rapid monophasic HBsAg decline during nucleic-acid polymer-based therapy predicts functional cure. Hepatol. Commun. 7 https:\/\/doi.org\/10.1097\/hc9.0000000000000205 (2023).","DOI":"10.1097\/hc9.0000000000000205"},{"key":"10473_CR23","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GLH Wong","year":"2022","unstructured":"Wong, G. L. H., Gane, E. & Lok, A. S. F. How to achieve functional cure of HBV: stopping nucs, adding interferon or new drug development? J. Hepatol. 76, 1249\u20131262. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.024 (2022).","journal-title":"J. Hepatol."},{"key":"10473_CR24","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","volume":"443","author":"M Iwamoto","year":"2014","unstructured":"Iwamoto, M. et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem. Biophys. Res. Commun. 443, 808\u2013813. https:\/\/doi.org\/10.1016\/j.bbrc.2013.12.052 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10473_CR25","doi-asserted-by":"publisher","first-page":"16178","DOI":"10.1038\/s41598-019-52824-z","volume":"9","author":"F Pastor","year":"2019","unstructured":"Pastor, F. et al. Direct interaction between the hepatitis B virus core and envelope proteins analyzed in a cellular context. Sci. Rep. 9, 16178. https:\/\/doi.org\/10.1038\/s41598-019-52824-z (2019).","journal-title":"Sci. Rep."},{"key":"10473_CR26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/infdis\/jir485","volume":"204","author":"J Inoue","year":"2011","unstructured":"Inoue, J. et al. Enhanced replication of hepatitis B virus with frameshift in the precore region found in fulminant hepatitis patients. J. Infect. Dis. 204, 1017\u20131025. https:\/\/doi.org\/10.1093\/infdis\/jir485 (2011).","journal-title":"J. Infect. Dis."},{"key":"10473_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.virol.2009.09.028","volume":"395","author":"J Inoue","year":"2009","unstructured":"Inoue, J. et al. Enhanced intracellular retention of a hepatitis B virus strain associated with fulminant hepatitis. Virology 395, 202\u2013209. https:\/\/doi.org\/10.1016\/j.virol.2009.09.028 (2009).","journal-title":"Virology"},{"key":"10473_CR28","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/hep4.1709","volume":"5","author":"M Ninomiya","year":"2021","unstructured":"Ninomiya, M. et al. The Exosome-Associated tetraspanin CD63 contributes to the efficient assembly and infectivity of the hepatitis B virus. Hepatol. Commun. 5, 1238\u20131251. https:\/\/doi.org\/10.1002\/hep4.1709 (2021).","journal-title":"Hepatol. Commun."},{"key":"10473_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bbrep.2018.03.003","volume":"14","author":"T Umetsu","year":"2018","unstructured":"Umetsu, T. et al. Inhibitory effect of Silibinin on hepatitis B virus entry. Biochem. Biophys. Rep. 14, 20\u201325. https:\/\/doi.org\/10.1016\/j.bbrep.2018.03.003 (2018).","journal-title":"Biochem. Biophys. Rep."},{"key":"10473_CR30","doi-asserted-by":"publisher","first-page":"e0129889","DOI":"10.1371\/journal.pone.0129889","volume":"10","author":"R Yan","year":"2015","unstructured":"Yan, R. et al. Spinoculation enhances HBV infection in NTCP-Reconstituted hepatocytes. PLoS One. 10, e0129889. https:\/\/doi.org\/10.1371\/journal.pone.0129889 (2015).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10473-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T13:03:39Z","timestamp":1751979819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10473-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10473"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-10473-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24344"}}